Medical Opinion publishes expert perspectives on clinical care, public health, policy, and technology. Each essay is clearly labeled as commentary, discloses conflicts, and cites key evidence.
In April 2020, people around the globe were struggling to come to grips with the strictures of unprecedented societal shutdowns aimed at slowing the spread of Covid-19. Flattening the curve, in 2020-speak.
Nancy Cox, who for decades was a global leader in influenza research, has died. Cox headed the influenza team at the Centers for Disease Control and Prevention for 22 years, shepherding it
The Food and Drug Administration will accelerate its review of psychedelic drugs developed by Compass Pathways, the Usona Institute, and Transcend Therapeutics for mental health disorders, as part of the Trump administration’s
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s my birthday tomorrow. Read the rest…
WASHINGTON — President Trump heralded a drug pricing agreement with Regeneron on Thursday, closing the last of 17 deals initially sought by the White House last year. Regeneron, as part of the
Heart disease and cancer are the leading causes of death in the United States, but it is rare that cancer makes its way to the heart. It’s an observation that clinicians have
The days of “Just Say No,” it seems, are long gone. Over the weekend, President Trump signed an executive order to increase the availability of certain psychedelics as treatments for mental health
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Sarah
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning, we made it to Thursday. Thanks for reading. Read the rest…
WASHINGTON — Health secretary Robert F. Kennedy Jr. once said there are no vaccines that are safe and effective. On Wednesday, he seemed to have changed his tune. Across two Senate hearings,